Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Effects of Rosuvastatin on Aortic Stenosis Progression
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 378
- Registration Number
- NCT00800800
- Locations
- 🇨🇦
Research site, St. John's, Canada
Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 2998
- Registration Number
- NCT00786136
- Locations
- 🇨🇳
Renmin Hospital Of Wuhan University, WuHan, Hubei, China
🇨🇳ShenZhou Hopital Of ShenYang Medical College, ShengYang, Liaoning, China
🇨🇳WuHan Asia Heart Hosital, WuHan, Hubei, China
Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00783042
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
A Diabetes Study to Treat A Population Previously Not at Target
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 598
- Registration Number
- NCT00747149
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Effects of Crestor on Inflammation of Atherosclerotic Plaques
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00689416
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 934
- Registration Number
- NCT00683618
- Locations
- 🇨🇳
Research Site, Tianjin, China
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
- Conditions
- Interventions
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00681395
- Locations
- 🇺🇸
Site Reference ID/Investigator# 8089, Orlando, Florida, United States
Rosuvastatin in Rheumatoid Arthritis (RORA)
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 50
- Registration Number
- NCT00679510
- Locations
- 🇬🇧
University of Dundee, Dundee, United Kingdom
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT00680017
- Locations
- 🇺🇸
Site Reference ID/Investigator# 8095, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 22812, Dallas, Texas, United States
🇺🇸Site Reference ID/Investigator# 8136, Atlanta, Georgia, United States
Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 250
- Registration Number
- NCT00673582
- Locations
- 🇨🇦
The St. Paul's Hospital HIV Metabolic Clinic & The BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.